Fig. 3
Elevated pAkt level in ptena-/-ptenb-/- mutants is suppressed by LY294002 and to a lesser extent by sunitinib. Wild-type (left lane of each blot) and ptena-/-ptenb-/- mutant (right lane of each blot) embryos were left untreated (-), were injected at the one-cell stage with ptena mRNA (pten), or were treated with 25 μM LY294002 (LY) or 20 μM sunitinib (S) from 72 hpf onwards. Single embryos were lysed at 4 dpf and the protein from individual embryos was isolated. The proteins were run on a denaturing SDS-polyacrylamide gel and transferred to PVDF membranes. After blocking, the blot was probed with phosphospecific anti-pAkt antibody (directed against pSer473), stripped and probed with Akt-specific antibody as a loading control. The number of individual embryos that were analyzed is: wild type, 24; mutant, 23; wild type + pten, 10; mutant + pten, 15; wild type + LY, 2; mutant + LY, 6; wild type + S, 5; mutant + S, 5. Representative blots are depicted here. The intensities of the bands were quantified (supplementary material Fig. S5). |